文献速递肝病

Bulevirtide单药治疗HDV相关肝硬化长达3年的安全性和有效性

Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
PubMed 文献 · J Hepatol · 2021-10-23

本文描述同情用药项目中HDV相关代偿期肝硬化患者接受Bulevirtide(BLV)单药治疗长达3年的结果。1例48周停药后出现病毒学和生化反弹,随后ALT正常化且HDV RNA和HBsAg低水平;2例持续治疗3年维持病毒学和生化应答,即使减量后仍维持。未记录安全问题,胆盐升高无症状。

要点

  • BLV单药持续3年可使HDV相关肝硬化患者获得良好病毒学和临床应答
  • 1例48周停药后出现反弹,但随后ALT正常化且HDV RNA和HBsAg低水平
  • 2例持续治疗3年维持应答,减量后仍维持,无安全问题

核心结论

  • 持续给予BLV单药治疗3年可使对干扰素治疗有禁忌的HDV相关肝硬化患者获得极好的病毒学和临床应答。

研究设计与样本

  • 描述性研究:同情用药项目中,HDV相关代偿期肝硬化患者接受BLV 10 mg/天起始剂量治疗长达3年,并监测HBcrAg、HBV RNA及HDV/HBV特异性T细胞标志物。

主要发现

  • 1例患者在48周达到病毒学和生化应答后停用BLV,出现初始病毒学和生化反弹,随后ALT正常化并伴低HDV RNA和HBsAg水平。
  • 2例持续治疗3年的患者在整个治疗期间维持病毒学和生化应答,即使减量后仍维持。
  • 1例晚期代偿期肝硬化患者肝功能检查显著改善,食管静脉曲张消失,自身免疫性肝炎的组织学/实验室特征消退。
  • 未记录安全问题,胆盐升高无症状。
  • 所有患者血清HBV RNA水平始终检测不到,HBV核心相关抗原水平在长期BLV治疗期间呈渐进但适度下降;未检测到HDV特异性产干扰素-γ的T细胞。

临床怎么用

  • 对于有干扰素治疗禁忌的HDV相关代偿期肝硬化患者,可考虑持续BLV单药治疗并长期监测病毒学和生化应答。

局限性

  • 为同情用药项目中的少量患者描述性报告,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The entry inhibitor bulevirtide (BLV) received conditional approval from the EMA in July 2020 for the treatment of adult patients with compensated chronic hepatitis delta. However, the effectiveness and safety of BLV administered as monotherapy beyond 48 weeks in difficult-to-treat patients with HDV-related cirrhosis is presently unknown. Herein, we describe the first patients with HDV-related compensated cirrhosis who were treated with BLV (10 mg/day as a starting dose) for up to 3 years on a compassionate use program. Patients were also monitored for HBcrAg and HBV RNA levels, and HDV- and HBV-specific T-cell markers. In the patient who stopped BLV at week 48, after achieving a virological and biochemical response, the initial virological and biochemical rebound was followed by alanine aminotransferase normalization coupled with low HDV RNA and HBsAg levels. In the 2 patients treated continuously for 3 years, virological and biochemical responses were maintained throughout the treatment period even after dose reduction. In a patient with advanced compensated cirrhosis, liver function tests significantly improved, esophageal varices disappeared, and histological/laboratory features of autoimmune hepatitis resolved. Overall, no safety issues were recorded, as bile salt increase was asymptomatic. While serum HBV RNA levels remained undetectable in all patients, HBV core-related antigen levels showed a progressive, yet modest decline during long-term BLV treatment. No HDV-specific interferon-γ-producing T cells were detected, neither after HDV reactivation (after BLV withdrawn in Patient 1) nor during 3 years of BLV treatment. In conclusion, this report shows that continuous administration of BLV monotherapy for 3 years leads to excellent virological and clinical responses in patients with HDV-related cirrhosis who had contraindications to interferon-based therapies.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Loglio A, Ferenci P, Uceda Renteria SC, et al. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol. 2021. PMID: 34699951. doi:10.1016/j.jhep.2021.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。